Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.

Authors: Sano, D  Xie, TX  Ow, TJ  Zhao, M  Pickering, CR  Zhou, G  Sandulache, VC  Wheeler, DA  Gibbs, RA  Caulin, C  Myers, JN 
Citation: Sano D, etal., Clin Cancer Res. 2011 Nov 1;17(21):6658-70. doi: 10.1158/1078-0432.CCR-11-0046. Epub 2011 Sep 8.
Pubmed: (View Article at PubMed) PMID:21903770
DOI: Full-text: DOI:10.1158/1078-0432.CCR-11-0046

PURPOSE: To characterize tumor growth and metastatic potential in head and neck squamous cell carcinoma (HNSCC) cell lines in an orthotopic murine model of oral tongue cancer and to correlate TP53 mutation status with these findings. EXPERIMENTAL DESIGN: Cells from each of 48 HNSCC cell lines were orthotopically injected into the oral tongues of nude mice. Tumor volume, cervical lymph node metastasis, and mouse survival were recorded. Direct sequencing of the TP53 gene and Western blot analysis for the p53 protein after induction with 5-fluorouracil was conducted. Cell lines were categorized as either mutant TP53 or wild-type TP53, and lines with TP53 mutation were further categorized on the basis of type of mutation (disruptive or nondisruptive) and level of p53 protein expression. The behavior of tumors in these different groups was compared. RESULTS: These 48 HNSCC cell lines showed a wide range of behavior from highly aggressive and metastatic to no tumor formation. Mice injected with cells harboring disruptive TP53 mutations had faster tumor growth, greater incidence of cervical lymph node metastasis, and shorter survival than mice injected with cells lacking these mutations. CONCLUSIONS: HNSCC cell lines display a wide spectrum of behavior in an orthotopic model of oral cancer. Cell lines with disruptive TP53 mutations are more aggressive in this system, corroborating clinical reports that have linked these mutations to poor patient outcome.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 8547850
Created: 2014-02-26
Species: All species
Last Modified: 2014-02-26
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.